FDA Asks Drug-Maker to Stop Selling Opioid Opana ER

The U.S. Food and Drug Administration has asked Endo Pharmaceuticals to remove its opioid pain medication, reformulated Opana ER, from the market due to concerns about the drug’s potential for abuse. This is the first time the FDA has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse, the agency said on Thursday. The FDA’s decision is based on a review of data that showed a significant shift in the route of abuse of Opana ER, from nasal to injection, following the product’s reformulation. Injection abu...